retatrutide and liver Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide Doesn't ONLY Help With

In a phase 2 randomised controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest doses of retatrutide achieved a mean weight reduction of approximately 1724% of body weight over 48 weeks, depending on dose

Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying

You pay for a 28-day treatment plan that includes your consultation, prescription, and medication

If these symptoms tend to peak within the first 1224 hours after injection, choosing a time when you can rest or have a lighter schedule may be beneficial

In addition to the incretin effects, GLP-1 promotes satiety 11 and GIP promotes lipid storage and metabolic regulation 12,13,14,15